Literature DB >> 8595056

Propofol binding to human blood proteins.

P Altmayer1, U Büch, H P Büch.   

Abstract

The binding of the intravenous anesthetic propofol (CAS 2078-54-8) to human native plasma, hemoglobin and serum albumin was studied by means of equilibrium dialysis. Propofol binding to plasma over the large concentration range from 0.04 to 150 micrograms/ml was independent on the substrate concentration and amounted 97.4-98.6%. Serum albumin and hemoglobin also showed a marked binding for propofol. A 4% solution of albumin bound 88.7% and hemoglobin 86.2% of the anesthetic. In studies with constant protein concentration and variation of the propofol concentration a decrease of the percentage bound with increasing substrate concentration was seen for hemoglobin, indicating saturable binding sites. The opposite was found for the interaction between propofol and albumin: increase of the binding extent with increasing substrate concentration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8595056

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

1.  Reply

Authors: 
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

2.  Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol.

Authors:  E H Cox; C A Knibbe; V S Koster; M W Langemeijer; E E Tukker; R Lange; P F Kuks; H J Langemeijer; L Lie-A-Huen; M Danhof
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

3.  Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics.

Authors:  J X Mazoit; K Samii
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

4.  The Effects of Propofol on a Human in vitro Blood-Brain Barrier Model.

Authors:  Jason M Hughes; Olivia R Neese; Dylan D Bieber; Kirsten A Lewis; Layla M Ahmadi; Dustin W Parsons; Scott G Canfield
Journal:  Front Cell Neurosci       Date:  2022-05-11       Impact factor: 6.147

5.  Propofol at clinically relevant concentrations increases neuronal differentiation but is not toxic to hippocampal neural precursor cells in vitro.

Authors:  Jeffrey W Sall; Greg Stratmann; Jason Leong; Elliott Woodward; Philip E Bickler
Journal:  Anesthesiology       Date:  2012-11       Impact factor: 7.892

Review 6.  The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties.

Authors:  Yoshinori Kotani; Masamitsu Shimazawa; Shinichi Yoshimura; Toru Iwama; Hideaki Hara
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

7.  Inhibition of the cardiac Na⁺ channel α-subunit Nav1.5 by propofol and dexmedetomidine.

Authors:  Carsten Stoetzer; Svenja Reuter; Thorben Doll; Nilufar Foadi; Florian Wegner; Andreas Leffler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-12-15       Impact factor: 3.000

8.  Human physiologically based pharmacokinetic model for propofol.

Authors:  David G Levitt; Thomas W Schnider
Journal:  BMC Anesthesiol       Date:  2005-04-22       Impact factor: 2.217

9.  Chitosan Oligosaccharide Reduces Propofol Requirements and Propofol-Related Side Effects.

Authors:  Zhiwen Li; Xige Yang; Xuesong Song; Haichun Ma; Ping Zhang
Journal:  Mar Drugs       Date:  2016-12-21       Impact factor: 5.118

Review 10.  Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Biomed Res Int       Date:  2018-05-24       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.